PDSB PDS Biotechnology Corp: Enterprise Value-to-Revenue Multiple

Public company logo of PDS Biotech (PDSB)

PDS Biotechnology adheres to basic environmental standards when disposing of reagents. The historical EV/Sales level demonstrates current market expectation trends, while the 0.00 metric indicates the valuation status. PDS Biotechnology implements strict bioethics in its research; however, the lack of stable cash flows leaves its financial position dependent on new investments and the success of clinical trials.

Company Value to Revenue: PDS Biotechnology Corp (PDSB) for 11/23/2025 - 11/20/2026

PDS Biotechnology Corp - analytical breakdowns and key metrics (PDSB)

- share price and consensus valuation forecast:
Initial company analysis:PDS Biotech PDSB
Product sample of PDS Biotech

This indicator compares the total business value, including debt and cash, with sales volume, eliminating the impact of leverage on the valuation. By analyzing the current enterprise value-to-revenue ratio, an investor can see how the virtual model of PDS Biotechnology (PDSB), with its critical dependence on external contractors, affects the market multiple amid tight monetary policy.

Competitor analysis for PDS Biotechnology

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|werewolftx.com (HOWL) - Enterprise Value-to-Revenue Multiple|Immix Biopharma Inc. - EV/Sales Multiple|ALXO - EV/Sales Multiple|CUE: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP